MAIA Biotechnology is an early-stage drug developer focused on creating precision immunotherapy treatments for various cancer types. The company's primary candidate is Ateganosine, an experimental agent designed to target telomeres and is being tested in patients with non-small cell lung cancer. Founded in 2018 and based in Chicago, Illinois, the firm operates through subsidiary entities.
1Y: 1.40 (-9.7%) · range 0.87–2.95
entry readiness 45 · WEAK SETUP · exit proximity 0
Value area 1.28–1.45 · 33% of 120d volume overhead · moderate overhead
MAIA is a thinly-covered sub-$2 biotech where the evidence neither converges nor strongly conflicts — it just doesn't add up to a case yet. The one orthogonal positive (a single CEO insider buy) is offset by a weak, unconfirmed daily setup, a negative earnings surprise, and a double-top forming, with the daily lane itself sitting on WATCH rather than acting. The read turns on the fact that only one signal family has fired in 21 days, which caps conviction regardless of direction.
- form4 insider cluster: CEO bought $100,010 — the only contributing source firing, scored 0.440
- Buildup leg elevated at 70 within the conviction blend, and Markov trend UP with P(stay) 84%
- Cycle tagged ENTRY ZONE, indicating price is in a structurally interesting area
- Daily lane is WATCH, not OPEN — readiness only 45 [WEAK SETUP], setup unconfirmed
- Absolute score 39/100 HOLD/NEUTRAL with technical 35, and VScore just 28
- Chart pattern shows double_top:forming (score 0) — a mild structural warning
- Earnings surprise of -18.2% on record; no Monte Carlo simulation available to quantify risk
- Single-family coverage overall — dossier is thin, which itself limits any convicted read
Invalidated if: A daily-lane flip from WATCH to OPEN on a readiness break above ~confirmation (or a confirmed breakout invalidating the double-top) would turn this bullish; a completed double-top breakdown or another soft earnings print would turn it bearish.
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.440 | Sep 16, 2026 |
Not yet labeled — the study prices these as positions mature.